CLINICA 100 TOP 10: Roche Diagnostics
This article was originally published in Clinica
Roche Diagnostics remains at No 6 in our Clinica 100 and continues to hold on as leader of the IVD sector. While not the most acquisitive buyer, Roche has been a consistent shopper, adding mainly smaller, bolt-on technologies to its molecular diagnostics offering. In 2014, it made six acquisitions, mostly of undisclosed amounts or under $500m. It made the same number of acquisition in 2015, but it dug deeper in its pocket this year and signed a deal worth up to $1.2bn to gain a majority stake in Foundation Medicine, a molecular information and genomic analysis firm. See how Roche Diagnostics performed in the last five years.
Register for our free email digests: